Skip to main content
TipRanks
Go Ultimate75% OFF

Cell Impact AB (CI) AI Stock Analysis

2 Followers
SE:CI

Cell Impact AB

(Nasdaq OMX AB:CI)

Select Model
Rating:42Neutral
Price Target:SEK 0.01â–¼(-20.00% Downside)
Action:upgraded
Date:11/13/26

The score is held down primarily by severe operating losses and ongoing cash burn, despite a relatively low-leverage balance sheet. Technical indicators also point to a sustained downtrend with negative momentum. Valuation offers limited support because the company is loss-making (negative P/E) and no dividend yield is available.

Positive Factors
Low Balance-Sheet LeverageThe low debt burden gives Cell Impact greater financial flexibility than a highly leveraged industrial business. It can reduce the immediate pressure from interest and refinancing obligations, leaving more capacity to pursue operations, product development, or manufacturing expansion if performance improves.
Negative Factors
Severe Operating LossesCurrent operations are not generating adequate gross profit to cover the company’s cost base, producing severe operating and net losses. This weak profitability limits internally funded investment, makes execution more dependent on improvement in scale, and leaves earnings vulnerable over the next several quarters.

Cell Impact AB (CI) vs. iShares MSCI Sweden ETF (EWD)

-100%-75%-50%-25%0%25%SE:CI-95.18%EWD+15.64%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 4.40M
Dividend Yield
―
Average Volume (3M)
11.42M
Price to Earnings (P/E)
-0.1
Beta (1Y)
0.91
Revenue Growth
-15.92%
EPS Growth
62.91%
Country
Sweden
Employees
26
Sector
General
Sector Strength
55
Industry
Manufacturing - Metal Fabrication

Cell Impact AB Business Overview & Revenue Model

Company Description

Cell Impact AB (publ) is a Swedish firm that specializes in the global production and distribution of bipolar flow plates, which are crucial components for hydrogen fuel cells. The company's products include plates designed with meticulously precise...

Cell Impact AB Financial Statement Overview

Summary

Income statement and cash flow are very weak: TTM revenue is small (5.6M) with negative gross profit, deeply negative operating/net margins, and materially negative operating cash flow and free cash flow (about -31.0M and -31.7M). The main offset is a relatively low-leverage balance sheet (debt-to-equity ~0.07), but sustained losses and cash burn remain the dominant financial risk.

Income Statement

8Very Negative

Balance Sheet

62Positive

Cash Flow

12Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue5.63M5.57M37.33M47.26M76.81M71.35M
Gross Profit-148.82M-121.42M5.42M25.45M36.94M34.88M
EBITDA-43.91M-55.03M-71.45M-97.72M-86.22M-67.85M
Net Income-113.19M-131.98M-100.43M-121.40M-104.22M-79.85M
Balance Sheet
Total Assets141.13M163.37M261.25M381.93M401.51M238.72M
Cash, Cash Equivalents and Short-Term Investments11.23M10.86M20.39M99.89M164.67M28.56M
Total Debt8.48M32.54M30.92M42.75M44.70M19.51M
Total Liabilities19.51M42.34M42.16M78.56M77.17M96.10M
Stockholders Equity121.63M121.03M219.08M303.37M324.35M142.63M
Cash Flow
Free Cash Flow-31.74M-47.29M-76.66M-152.75M-174.32M-140.39M
Operating Cash Flow-31.02M-45.36M-62.23M-100.97M-105.93M-86.08M
Investing Cash Flow-712.00K2.30M-14.43M-51.78M-68.40M-54.32M
Financing Cash Flow36.31M33.68M-2.84M88.09M310.47M17.01M

Cell Impact AB Technical Analysis

Technical Analysis SentimentNeutral
Last Price0.01

Price Trends

50DMA0.03Negative
100DMA0.04Negative
200DMA0.08Negative

Market Momentum

MACD-0.00Negative
RSI49.51Neutral
STOCH23.81Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CI, the sentiment is Neutral. The current price of 0.01 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.03, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 49.51 is Neutral, neither overbought nor oversold. The STOCH value of 23.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:CI.

Cell Impact AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

SE:CI against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
SE:FLUOSE:FLUO45NeutralSEK 479.03M-6.58―――-23.57%
SE:OSSDSE:OSSD45NeutralSEK 387.19M-7.74――-11.89%-11.85%
SE:ANNXSE:ANNX44NeutralSEK 78.81M-2.05―――7.33%
SE:CISE:CI42NeutralSEK 19.90M-0.05――-15.92%62.91%
SE:SCIBSE:SCIB40UnderperformSEK 135.27M-0.71-415.20%―54.94%47.64%
SE:CLBIOSE:CLBIO39UnderperformSEK 371.09M-28.83――54.37%52.22%

* General Sector Average

Performance Comparison

-50%0%50%100%SE:CISE:SCIBSE:ANNXSE:OSSDSE:CLBIOSE:FLUODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:CI and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:CICell Impact AB0.01-0.27-94.79%
SE:SCIBSciBase Holding AB9.58-10.31-51.83%
SE:ANNXAnnexin Pharmaceuticals AB9.04-15.98-63.87%
SE:OSSDOssDsign AB3.50-7.48-68.12%
SE:CLBIOCorline Biomedical AB14.20-5.60-28.28%
SE:FLUOFluoGuide A/S29.30-10.70-26.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026